Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Intravenous injection stable concertrated clear solution containing rifamycin after dilution

A rifamycin and drug technology, applied in the field of concentrated clear solution, can solve the problems of affecting the curative effect, toxicity and the like

Inactive Publication Date: 2005-12-21
CHENGZHENG XINKAI PHARMA FACTORY SUZHOU
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] The common feature of the above-mentioned prior art is that the prepared solution all contains moisture, so it is easy to decompose into rifamycin S (required to be less than 2.0%), rifamycin B (required to be less than 0.5%) and other total impurities (required to be less than 2.0%), which not only affects its curative effect, but may also be toxic to humans

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Intravenous injection stable concertrated clear solution containing rifamycin after dilution
  • Intravenous injection stable concertrated clear solution containing rifamycin after dilution

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0040] The formulation examples of the stable clear solution of the active compound involved in the present invention are listed below to further explain the present invention, but are not limited by these examples.

[0041] (1) Rifamycin 25.0g

[0042] Propylene glycol 500.0ml

[0043] Dimethylformamide Add to 500.0ml

[0044] Total 1000.0ml

[0045] (2) Rifamycin 250.0g

[0046] Add propylene glycol to 1000.0ml

[0047] Total 1000.0ml

[0048] (3) Rifamycin 150.0g

[0049] Propylene glycol 800.0ml

[0050] Add to 200.0ml polyethylene glycol

[0051] Total 1000.0ml

[0052] (4) Rifamycin 120.0g

[0053] Absolute ethanol 500.0ml

[0054] Propylene glycol 300.0ml

[0055]Add polyethylene glycol to a total of 1000.0ml

[0056] (5) Rifamycin 120.0g

[0057] Absolute ethanol 400.0ml

[0058] ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a stable concentrated clear solution containing rifamycin medicine. After said stable concentrated clear solution is diluted, it can be used for intravenous injection. Said solution includes active compound of rifamycin medicine and solvent, every milliliter contains 0.025g-025g of active substance rifamycin, and the described solvent is non-aqueous medicinal solvent, and the dosage of the described solvent must make the described active substance be dissolved and keep stable.

Description

technical field [0001] The invention relates to a stable concentrated clear solution containing rifamycins which can be used for intravenous injection after dilution. Background technique [0002] Rifamycin (English name: Rifamycin Sodium) is a broad-spectrum antibiotic, which has a strong bactericidal effect on Staphylococcus aureus and Mycobacterium tuberculosis. Severe staphylococcal infection, such as methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE) infection; Legionella infection, etc. The effective rate of clinical use is as high as 80%-90%. It also has an effect on chlamydia and certain viruses at high concentrations. It is characterized by strong bactericidal properties (can enter cells), high blood concentration, excretion from the biliary tract, and low toxicity. The distribution in the body is the highest in the liver and bile, and the therapeutic concentration can also be reached in the kidney, lung, h...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/395
Inventor 刘志祥王金陵曹喜华藏建英杨南林阎政郑娜
Owner CHENGZHENG XINKAI PHARMA FACTORY SUZHOU
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com